FDA OK's Onivyde In Pancreatic Cancer; Warnings Smack Merrimack
This article was originally published in Scrip
Merrimack Pharmaceuticals Inc. won the FDA's approval on Oct. 22 to market Onivyde (irinotecan liposome injection), an topoisomerase inhibitor, as a treatment in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
You may also be interested in...
CEO removed as part of 22% staff cut as Merrimack looks to increase runway while awaiting data to add first-line pancreatic cancer to the Onivyde label.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.